Hansoh Pharma (翰森制药) IPO: Strong Cornerstone Line-Up, Upside at Low End
Hansoh Pharma, the largest pharmaceutical listing in Hong Kong this year, launched its book building today. In our previous insights (links...
864 Views
Hansoh Pharma (翰森制药) IPO: Inebilizumab License-In from Viela Bio a Symbolic Deal
Just ahead of the launch of Hansoh Pharma's book building for its USD 1bn IPO, news reported today that Hansoh inked a license-in agreement with...
805 Views
ECM Weekly (25 May 2019) - ESR Cayman, Hansoh Pharma, Tai Hing, China East Edu, Haitong UniTrust
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
662 Views
Hansoh Pharma (翰森制药) IPO: Thoughts on Valuation
Hansoh Pharma has started pre-marketing its IPO to raise USD 1bn in its IPO. In our previous insights, we covered the company's major products and...
735 Views
Hansoh Pharma (翰森制药) IPO: Competitive Landscape of HS-10296, the 3rd Gen EGFR TKI for Lung Cancer
Hansoh Pharma has started pre-marketing its IPO to raise USD 1bn in its IPO. In our previous insights, we covered the company's major products and...
896 Views